Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute).

Article Details

Citation
Copy to clipboard

Yeates C

Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute).

Curr Opin Investig Drugs. 2002 Oct;3(10):1446-52.

PubMed ID
12431016 [ View in PubMed
]
Abstract

Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis. Phase III trials for the treatment of visceral leishmaniasis had been initiated by March 2002, at which time GlaxoSmithKline hoped to file an MAA in 2003. By 1999, the compound had also undergone phase I trials in HIV-infected individuals for the treatment of Pneumocystis carinii infection. Preclinical studies have been conducted in primates and rodents for the potential treatment of Babesia microti infection.

DrugBank Data that Cites this Article

Drugs